Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Degendering Symptom Assessment to Appropriately Evaluate for Malignancies

Premiere Date: Monday, May 23, 2022

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Tuesday, May 23, 2023
Note: Credit Is No Longer Available


Don S. Dizon, MD, FACP, FASCODon S. Dizon, MD, FACP, FASCO (Moderator)
Professor of Medicine and Professor of Surgery, Brown University
Director, The Pelvic Malignancies Program and Hematology-Oncology Outpatient Clinics, Lifespan Cancer Institute
Head, Community Outreach and Engagement, Legoretta Cancer Institute at Brown University
Director, Medical Oncology and the Oncology Sexual Health First Responders Clinic
Rhode Island Hospital
Providence, RI

Ash B. Alpert, MD, MFAAsh B. Alpert, MD, MFA 
AHRQ T32 Post-Doctoral Fellow in Health Services Research
Center for Gerontology and Healthcare Research
Department of Health Services, Policy & Practice
Brown University School of Public Health
Providence, RI

Statement of Need

Gendered and heterosexual presumptive care settings are commonplace in health care and alienate sexual and gender minority (SGM) patients from receiving routine cancer screenings. Gendered references to gynecologic and breast cancers as “women’s cancer,” and prostate cancer as “men’s cancer,” are deeply rooted into the health care system. By disentangling gender from cancer and breaking down heteronormative assumptions, clinicians can provide equitable care to all patients, and critically, improve outcomes for SGM patients. National surveys and published literature show that SGM patients often delay cancer screenings and care for fear of stigma or mistreatment, which may result in later cancer diagnoses and poorer outcomes. Health care professionals who are trained in culturally relevant and humble care engage patients in discussions about the need for cancer screenings. Providing equitable care to SGM patients requires changing the practice environment, patient communications, and information-gathering processes to create an inclusive, affirming, and welcoming experience for diverse genders and sexual orientations. These changes can only be effective if the entire team, clinical and non-clinical staff alike, are trained in culturally relevant and humble education as they interact and care for SGM patients.

In this CMEO BriefCase, faculty will use case-based learning to demonstrate the challenges specifically related to gender assumptions that transgender and non-binary patients encounter when trying to access health care. Faculty will then provide learners with best practices on approaching conversations about cancer screening based on anatomy present, not by gender.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Apply efficacious and non-gendered approaches to symptom assessment.

Financial Support

Supported by an educational grant from Merck Sharpe & Dohme Corp.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in oncology, obstetrics, gynecology, infectious disease and/or primary care

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Dizon reports the following financial relationships:

Consultant: DSMB/IDMC activities for AstraZeneca and Clovis Oncology.

Research Institutional Support: Bristol Myers Squibb and Pfizer Inc.

Other financial or material support: Board member for the LGBTQ Cancer Network.

Dr. Alpert reports no financial relationships.

The following Peer Reviewer and CME Outfitters staff have no financial relationships to disclose:

  • Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
  • Julie Strickland, PharmD (planning committee)
  • David Modrak, PhD (planning committee)
  • Kathleen Blake, PhD (planning committee)
  • Thomas Mitchell (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download